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CLINICAL REPORT
Acta Derm Venereol 2007; 87: 144–148 
Mortality in Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) is high. Apart from intensive 
supportive therapy, no generally accepted specific treat-
ment regimen exists. The role of corticosteroids in SJS/
TEN is controversial. It is possible that high-dose pulse 
therapy with corticosteroids might be an improvement 
on long-term lower dose therapy, by combining higher 
efficacy with a diminished risk both of infection and of 
delayed wound healing. The aim of this study was to eva-
luate the efficacy of dexamethasone pulse therapy with 
respect to mortality and healing time of patients with 
SJS/TEN. A small, uncontrolled series of consecutive in-
patients with SJS/TEN was treated with dexamethasone 
pulse therapy. The efficacy of this treatment was assessed 
retrospectively using SCORTEN. Twelve patients were 
included over a period of 10 years. One patient died, 
while SCORTEN predicted a fatal outcome of 4 patients. 
Stabilization was reached after 2.3 days on average, 
total re-epithelialization after 13.9 days. The results of this 
study bear no statistical relevance due to the small num-
ber of patients. In conclusion, short-term dexamethasone 
pulse therapy, given at an early stage of the disease, may 
contribute to a reduced mortality rate in SJS/TEN with-
out increasing healing time. A larger controlled trial is 
warranted to investigate further the use of dexamethaso-
ne pulse therapy in SJS/TEN. Key words: toxic epidermal 
necrolysis; Stevens-Johnson syndrome; dexamethasone; 
pulse therapy.
(Accepted November 7, 2006.)
Acta Derm Venereol 2007; 87: 144–148.
Sylvia H. Kardaun, MD, Center for Blistering Diseases, 
Department of Dermatology, University Medical Cen-
ter Groningen, University of Groningen, Hanzeplein 
1, NL-9713 GZ Groningen, The Netherlands. E-mail: 
s.h.kardaun@derm.umcg.nl
Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are rare but serious mucocutaneous 
reactions with extensive epithelial sloughing and sys-
temic symptoms, most often caused by drugs (1). More 
than 100 drugs have been associated with SJS/TEN, most 
often implicated are anti-epileptics, sulphonamides, β-
lactam antibiotics, non-steroidal anti-inflammatory drugs 
and allopurinol. SJS and TEN are part of a spectrum, 
which is artificially divided into 3 groups: SJS when 
the total detached and detachable body surface area 
(TBSA) is less then 10%, TEN when it is over 30%, and 
SJS/TEN-overlap when it is between 10% and 30% (2). 
The incidence of SJS is 1.2–6 per million per year and 
that of TEN 0.4–1.2 per million per year (1). Mortality 
rates reported in the literature vary due to differences 
in the definition of SJS and TEN, in populations and in 
treatment, but they are generally high. In adults mortality 
due to TEN is most often cited as 30–50% (1, 3–5). Sepsis 
and multi-organ failure are the main causes of death. Re-
covery is usually slow and may take 3–6 weeks (1). As a 
rule skin lesions heal without scarring, whereas mucosal 
scarring and strictures are frequent late complications. 
Late eye complications, potentially leading to blindness, 
occur in up to 50% of cases (6).
Apart from intensive supportive therapy, a generally 
accepted regimen for specific treatment of SJS/TEN 
is lacking. Treatment options include systemic cortico-
steroids, intravenous immunoglobulin therapy (IVIG), 
other immunosuppressive therapy, or no systemic 
treatment. Historically high-dose corticosteroids were 
advocated, but since the mid-1980s the use of cortico-
steroids in SJS/TEN has been controversial and is even 
considered detrimental by some authors (1, 7–9).
Intravenous (i.v.) pulse therapy with corticosteroids is 
used in severe, often autoimmune, diseases, as it is as-
sumed to share high efficacy with fewer side-effects than 
long-term lower dose corticosteroids. It has been used 
in dermatology since 1982 for several dermatological 
diseases that are often refractory to standard therapy, 
such as pyoderma gangrenosum and pemphigus (10). 
Although we demonstrated recently that there was no 
benefit of giving long-term adjuvant oral corticosteroid 
pulse therapy in addition to conventional treatment in 
patients with pemphigus vulgaris, the hypothesis that i.v. 
corticosteroid pulse therapy could be useful in TEN is 
still valid, since the pathomechanism of both diseases is 
different, and corticosteroid pulse therapy is applied as 
short-term monotreatment in TEN (11). There are only 
a few case reports describing pulse therapy in TEN (12, 
13). Initially, 1000 mg methylprednisolone was usually 
used, but recently dexamethasone has often been chosen 
for pulse therapy because it combines a strong immuno-
suppressive glucocorticoid with a negligible mineralo-
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corticoid effect. We studied the effect of dexamethasone 
pulse therapy (DPT) in 12 patients with SJS/TEN.
METHODS
From 1993 to 2003, we treated 12 consecutive patients who 
were referred to our department with SJS/TEN, using a stan-
dardized care protocol that did not require ethics review from 
our institution. All data were analysed retrospectively.
After anamnesis and physical examination, diagnosis was 
verified by histopathology of direct fresh-frozen sections of the 
skin, enabling quick diagnosis and differentiation from other 
diseases, especially staphylococcal scalded skin syndrome. Di-
agnosis was subsequently confirmed by routine histopathology, 
while immunofluorescence analysis of the skin and serum was 
performed in order to exclude immuno-bullous diseases. The 
date of onset of disease was determined from the patient’s medi-
cal history. Assessment of drug culpability (i.e. the empirical 
risk of a drug and the time-relation between drug use and the 
adverse reaction) was also based on the patient’s history. All 
suspected and non-essential drugs were stopped. Demographic 
and specific disease data are presented in Table I. 
Specific systemic therapy was started as soon as the diagnosis 
was established. In the first 4 patients we combined i.v. dexa-
methasone 100 mg, given within 30–60 min on 3 consecutive 
days, with one dose of cyclophosphamide 500 mg on the first 
day, analogous to the pulse for pemphigus vulgaris used by 
Pasricha (14). After the fourth patient, cyclophosphamide was 
omitted and the regimen changed to i.v. dexamethasone 1.5 
mg/kg body-weight as pulse therapy for 3 consecutive days. 
The patients were seen by a multidisciplinary team and 
received intensive supportive care according to a standard 
protocol. This included early fluid and electrolyte replacement, 
aggressive nutritional supplementation, and monitoring of vital 
functions. An ophthalmologist was routinely consulted about 
daily eye care. Meticulous wound care included lubricants, 
topical antibiotics and non-adhesive silicone wound dressings. 
Nursing was barrier protected and the patients were treated on 
an air-fluidized bed in a specialized humidity- and temperature-
controlled unit with, for aseptic reasons, a laminar down-flow 
stream. Epidermal involvement and TBSA were charted daily 
to determine the date of arrest of progression and of complete 
re-epithelialization (Table II). Additional investigations, inclu-
ding haemograms, biochemical tests, urine analysis, coagulation 
tests, fluid balance, body weight and bacteriological analysis, 
were performed on a regular basis. The use of lines and cathe-
ters was avoided as much as possible, and the venous line 
was maintained as short as possible. H2-blocking agents were 
administered in case of a history of gastric upset. To prevent 
intestinal Candida overgrowth we supplied oral nystatin, and for 
thrombosis prophylaxis nadroparin was given subcutaneously. 
Pain killers and sedatives were provided as needed. Antibiotic 
prophylaxis was not given, but antibiotics were supplied imme-
diately when clinically warranted. After discharge, a follow-up 
of 8±2 weeks was performed, and in cases where late sequelae 
were observed, also 2 years later.
SCORTEN, a validated TEN-specific severity-of-illness-
score, ranking severity and predicting mortality, was calculated 
retrospectively to assess the efficacy of DPT. SCORTEN is 
based on 7 independent risk factors (age, heart rate, malignancy, 
TBSA, and serum urea, bicarbonate and glucose levels). The 
predicted mortality progressively depends on the number of 
factors present (15).
RESULTS
Twelve consecutive patients (6 males, 6 females) were 
treated. Their mean age was 55.6 years (age range 
15–84 years). TBSA and characteristic cutaneous 
findings led to the classification of 1 SJS, 4 SJS/TEN-
overlap and 7 TEN. In all patients, 2 or more mucosae 
were affected. The mean SCORTEN on admission was 
2.8 (range 0–5) and predicted a mortality of 4 cases 
(25%). The mean delay between occurrence of first 
blister and first DPT was 2.8 days (range 1–6 days). 
Disease stabilization was achieved after a mean of 2.3 
days (range 1–5 days) after DPT. The mean time of 
healing (not stabilization) was strongly influenced by 
patient 1, who had extensive pre-existing burn scars. 
When we exclude these data, healing time from first 
DPT was 13.9 days (range 8–24 days), while from first 
blister it was 16.8 days (range 10–30 days). 
Patient 7 died; according to the consulting neurologist 
the cause of death was brain oedema due to metastasis, 
while his skin had practically healed. All other patients 
survived without major sequelae. Sepsis was found in 
patients 1 and 2, and suspected in patient 5. In addition, 
patients 1 and 5 had serologically proven herpes simplex 
virus (HSV) type 1 infection while leukopaenia was 
present, probably contributing to protracted healing. 
In patient 1 neutropaenia (0.04×103/µl) accompanied 
severe leukopaenia (0.4×103/µl). In patients 2 and 3 the 
respiratory tract was involved, leading to respiratory 
insufficiency; patient 3 needed mechanical ventilation. 
Though all patients experienced eye involvement in the 
acute phase, late sequelae were relatively mild and severe 
impaired vision was not encountered. Patients 2 and 8 
developed mild trichiasis, while patients 2 and 12 were 
left with dry eyes. Five patients (nos 2, 3, 4, 8 and 12) 
experienced hyper- and/or hypo-pigmentation of the skin, 
Table I. Clinical characteristics of patients with toxic epidermal 

















1 71/M 26 32 5 TEN 4
2 33/M 45 62 4 TEN 2
3 44/F 30 72 5 TEN 2
4 15/M 3 9 3 SJS 0
5 62/F 60 70 3 TEN 3a
6 70/F 18 19 3 SJS/TEN 3
7 78/M 23 41 2 TEN 5a
8 53/F 53 61 4 TEN 3 
9 58/F 11 20 2 SJS/TEN 3b
10 77/M 6 19 2 SJS/TEN 3
11 84/F 20 29 2 SJS/TEN 3
12 22/M 25 48 2 TEN 2c
Mean 55.6 26.7 40.2 3.1 2.8
aBrain tumour/metastasis.
bSystemic lupus erythematosus (SLE). 
cBone marrow transplant for haematological malignancy.
TBSA, total detached and detachable body surface area, %.
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most often transient. Hypohidrosis and dystrophic nails 
were observed in patient 8. Apart from slight transient 
glycaemia in some patients that might have been caused 
by dexamethasone, we did not observe any side-effects 
of dexamethasone.
DISCUSSION
The pathophysiology of SJS/TEN is not yet fully elu-
cidated, although significant progress has been made. 
Massive accelerated apoptosis has been proposed as the 
main mechanism underlying keratinocytic death in SJS/
TEN. Several pathways can lead to apoptosis. CD8-posi-
tive T cells and macrophages play an important role 
in the extensive epithelial necrosis and subepithelial 
detachment (16). Various (pro)inflammatory cyto-
kines including tumour necrosis factor (TNF)-α may 
contribute to epidermal cell death, as well as to fever 
and malaise. It has been suggested that, in SJS/TEN, 
apoptosis is mediated principally through activation of 
the Fas receptor by increased Fas ligand expression, 
but others have suggested that it is mediated mainly 
by TNF-α, perforin and granzyme B. Interferon-γ up-
regulation of keratinocytes also plays a role (17–19). 
In SJS/TEN the barrier function of the skin is lost due 
to full-thickness epithelial necrosis. Hence, disturbance 
of fluid, protein, and electrolyte balance leading to 
hypovolaemic shock and local and systemic infection 
with the threatening of sepsis, often leading to multi-
organ failure, are the most important causes of death. 
The main point in dealing with SJS/TEN patients is to 
restore the barrier function of the skin and mucosae as 
quickly as possible and in the meantime prevent the 
effects of this barrier loss. 
Knowledge of the treatment of SJS/TEN rests greatly 
on anecdotal observations, empirical experience and re-
trospective studies. Apart from direct withdrawal of the 
culprit drug and supportive care, there are no generally 
accepted guidelines for the specific treatment of SJS/
TEN, and few controlled clinical trials have been perform-
ed due to the rarity and severity of the disease (5, 19). 
Several specific treatment options have been proposed 
on theoretical grounds. Some with promising results and 
others, e.g. thalidomide, with increased mortality, pos-
sibly due to paradoxically enhanced TNF-α production 
(4, 19). The supposed rationale for IVIG is its capacity to 
inhibit activation of the death receptor by Fas-blocking 
antibodies, but its clinical results were contradictory (3, 
5, 17, 20, 21). The use of corticosteroids in SJS/TEN 
is controversial (7–10, 22, 23). The precise action of 
corticosteroids in inflammatory diseases is still not 
well understood. They have pleomorphic immune-mo-
dulating effects, e.g. through inhibition of numerous 
cytokines (10). Nowadays the use of corticosteroids 
in SJS/TEN is generally not advocated because of the 
possibility of delayed healing and the risk of infection 
(7, 9, 23). However, this opinion is based on only a 
few case series. Moreover, some cases in which it was 
stated that a better outcome was related to avoidance 
of corticosteroids had in fact taken corticosteroids for 
a mean of 3.5 days prior to referral. The general ne-
gative opinion of corticosteroids is probably because 
they are often given too late, in too low a dose, and for 
too long during the process. During the healing phase 
corticosteroids may indeed impair wound healing and 
promote sepsis. However, short courses of high-dose 
corticosteroids in early SJS/TEN have a good rationale, 
as immune mechanisms are directly responsible for 
the cascade of events leading to apoptosis. Hence, we 
Table II. Suspected drugs and course of the disease (in days) before and after dexamethasone pulse therapy (DPT)









1b Sulphamethoxazole + trimethoprim 2c 1 2 72 73 Burn scars, HSV
2b Acetylsalicylic acid  <14 3 2 15 18
3b Carbamazepine 12 1 2 17 18
4b Carbamazepine 14 2 2 8 10
5 Phenytoin 36d 6 2 24 30 Late referral, HSV
6 Allopurinol 5 4 1 14 18
7 Phenytoin 37d 1 3 9 10
8 Carbamazepine 17 2 2 17 19
9 Omeprazole 29d 4 3 14 18
10 Amoxicillin + clavulanic acid 4 3 5 14 17
11 Terbinafine 19 2 1 12 14
12 Sulphamethoxazole + trimethoprim 10 4 3 9 13
Mean 1–12 2.8 2.3 18.8 21.5 Overall
Mean 2–12 2.9 2.4 13.9 16.8 Excluding case 1
aLag time: time between first drug administration and first blister.
bAlso received cyclophosphamide 500 mg on day 1. 
cEight years earlier: toxic epidermal necrolysis after sulphamethoxazole + trimethoprim.
dChronic corticosteroid use: daily dose equivalent to 15–30 mg prednisolone.
HSV: herpes simplex virus.
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challenged the general opinion of corticosteroids being 
detrimental in the treatment of SJS/TEN.
Dexamethasone is a potent glucocorticoid (about 
7 times as potent as the same dose of prednisolone) 
with a continuous action level, due to its relative 
long biological half-life (36–54 h). It has pleomorp-
hic effects on the immune system and may inhibit 
epidermal apoptosis by several mechanisms: inhi-
bition of T-cell activated apoptosis by suppression 
of various cytokines such as TNF-α; inhibition of 
interferon-γ induced apoptosis; and inhibition of Fas-
 mediated keratinocyte apoptosis (10, 24). 
We gave DPT 1.5 mg/kg i.v. in 30–60 min on 3 con-
secutive days, thus avoiding long-term use of cortico-
steroids. Cyclophosphamide, added in the pemphigus 
regimen to prevent relapses, was omitted after patient 
4 (see table II), as relapses are not to be expected after 
withdrawal of the culprit drug. We saw no significant 
change in outcome and healing time. 
Patients 5 and 7 had metastatic brain tumours, and 
patient 9 had systemic lupus erythematosus, for which they 
chronically received corticosteroids. These patients deve-
loped the SJS/TEN reaction after a longer lag time (time 
between first drug administration and first blister). This 
phenomenon has been described previously (22); however, 
in patients 5 and 7 it might also be attributed to the culprit 
drug phenytoin, known for its potentially long lag time. 
Leukopaenia, regularly encountered in TEN, occurred in 
patients 5 and 1, in the latter neutropaenia was also pre-
sent. Both patients experienced sepsis and HSV infection, 
probably attributing to delayed wound healing.
The efficacy of DPT was evaluated according to ar-
rest of further epidermal or mucosal detachment, heal-
ing time in days, outcome and sequelae. The patients 
stabilized after an average of 2.3 days, while total re-
epithelialization was reached after 13.9 days. Despite 
SCORTEN predicting a mortality of 4 patients, only one 
died. Serious late sequelae of the mucosae, especially 
of the eyes were not found.
Comparison with published results is difficult. Most 
records of therapeutic trials in TEN are case series 
without controls. We calculated SCORTEN as validated 
predictive score for the outcome in SJS/TEN. 
In a large, multi-centre, epidemiological study the 
average period for stabilization was 4 days for SJS and 
5.8 days for TEN. Healing was almost complete 20–30 
days after hospitalization (25). In another study, therapy 
with IVIG was started 4.1 days after the start of the 
disease and healing was complete 18 days after admis-
sion. SCORTEN predicted 8.2 deaths, while 11 actually 
occurred (3). The authors concluded IVIG could not be 
recommended as a standard treatment for SJS/TEN. On 
the other hand, several IVIG studies mention surprising-
ly short periods of stabilization and/or healing (20, 21). 
In interpreting these results, one should also consider 
the time-lapse before treatment is started, as without 
treatment the period of progression may last 7–10 days 
(19, 25). Starting treatment late in the process implies 
that it is difficult to measure the effect of treatment on 
stabilization. Since we started quite early, we believe 
from our data that DPT did result in a relatively quick 
stabilization and healing and suggest that DPT may even 
have halted the process of apoptosis.
Although the results of this study bear no statistical 
relevance due to the small number of patients, we con-
clude that short-term DPT, given at an early stage of 
the disease, may contribute to a reduced mortality rate 
in SJS/TEN without increasing healing time. A larger 
controlled trial is warranted in order to investigate 
further the use of DPT in SJS/TEN.
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